
    
      The study will be conducted in a single centre and will consist of a single dose part and a
      multiple dose part.

      Seven single doses of CHF 6001 will be administered according to an escalation, alternate
      cross over scheme. Five multiple doses of CHF 6001 will be administered for 7 days according
      to a sequential escalation scheme.
    
  